Clinical Trials

284 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Neoplasms

NCT07464145 2026-03-11

RESCUE

393 enrolled

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT07445308 2026-03-03

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

120 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

236 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06972615 2026-02-17

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

37 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07268339 2025-12-05

TRAIN

328 enrolled

Phase 1 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07260162 2025-12-03

PERSEVERANCE

24 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06829823 2025-10-16

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

20 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07207824 2025-10-06

HERO

182 enrolled

Phase 2/3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT07198451 2025-09-30

GEM-IR-NMIBC

320 enrolled

Non-Muscle Invasive Bladder Neoplasms, Recurrence

NCT07189793 2025-09-24

OHAI-NMIBC-01

106 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07100184 2025-08-03

RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients

30 enrolled

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07064863 2025-07-17

BCG-TIME

31 enrolled

Phase NA Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT06678633 2025-05-29

T-Control® Safety for Cytostatics Management

16 enrolled

Phase NA Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06990061 2025-05-25

BRACE

50 enrolled

Phase NA Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06982690 2025-05-21

Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial

370 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Recurrence

NCT06630871 2024-10-10

A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

40 enrolled

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06588179 2024-09-19

SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt

58 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06310369 2024-07-22

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer

50 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06327932 2024-03-25

HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer

320 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06227065 2024-01-26

POLO

28 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05996952 2023-08-18

RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer

77 enrolled